Moomoo AIのまとめ
Senti Biosciences, a clinical-stage biotechnology company, reported a net loss of $71.1 million for the year ended December 31, 2023, compared to a net loss of $58.2 million for the previous year. The company's cash, cash equivalents, and short-term investments totaled $35.9 million as of December 31, 2023, down from $98.6 million the previous year. Operating expenses for the year were $95.3 million, with research and development expenses accounting for $32.2 million. The company recognized a gain of $21.9 million from the disposal of its Alameda facility to GeneFab, which also resulted in a reduction of longer-term operating expenses. Senti Biosciences has not generated revenue from product sales and anticipates continued significant losses and increased expenses as it advances its gene circuit platform technologies and clinical development of product candidates. The company's future plans include focusing on the clinical development of SENTI-202 and partnering its SENTI-301A program in China with Celest. Senti Biosciences has raised concerns about its ability to continue as a going concern beyond the next twelve months without additional funding.
Senti Biosciences, a clinical-stage biotechnology company, reported a net loss of $71.1 million for the year ended December 31, 2023, compared to a net loss of $58.2 million for the previous year. The company's cash, cash equivalents, and short-term investments totaled $35.9 million as of December 31, 2023, down from $98.6 million the previous year. Operating expenses for the year were $95.3 million, with research and development expenses accounting for $32.2 million. The company recognized a gain of $21.9 million from the disposal of its Alameda facility to GeneFab, which also resulted in a reduction of longer-term operating expenses. Senti Biosciences has not generated revenue from product sales and anticipates continued significant losses and increased expenses as it advances its gene circuit platform technologies and clinical development of product candidates. The company's future plans include focusing on the clinical development of SENTI-202 and partnering its SENTI-301A program in China with Celest. Senti Biosciences has raised concerns about its ability to continue as a going concern beyond the next twelve months without additional funding.
バイオテクノロジー企業のクリニカルステージのSenti Biosciencesは、2023年12月31日に終了した年度の純損失が7120万ドルで、前年の5820万ドルの純損失に比べ増加しました。同社の現金、現金同等物、および短期投資の合計は、前年の9860万ドルから、2023年12月31日時点で3590万ドルとなっています。年間の営業費用は9530万ドルであり、そのうち研究開発費用が3220万ドルを占めています。同社は、Alameda拠点のジェネファブへの売却により2190万ドルの利益を認識し、長期の営業費用を削減する結果となりました。Senti Biosciencesは、製品販売から収益を上...すべて展開
バイオテクノロジー企業のクリニカルステージのSenti Biosciencesは、2023年12月31日に終了した年度の純損失が7120万ドルで、前年の5820万ドルの純損失に比べ増加しました。同社の現金、現金同等物、および短期投資の合計は、前年の9860万ドルから、2023年12月31日時点で3590万ドルとなっています。年間の営業費用は9530万ドルであり、そのうち研究開発費用が3220万ドルを占めています。同社は、Alameda拠点のジェネファブへの売却により2190万ドルの利益を認識し、長期の営業費用を削減する結果となりました。Senti Biosciencesは、製品販売から収益を上げておらず、ジーン回路プラットフォーム技術の推進と製品候補の臨床開発を進めるにつれ、引き続き大幅な損失および増加する費用を予想しています。同社の将来の計画には、SENTI-202の臨床開発に重点を置き、SENTI-301Aプログラムを中国のCelestと提携することが含まれます。Senti Biosciencesは、追加資金がない場合、次の12か月以降も事業を継続する能力について懸念を示しています。
役に立った
役に立たない